Last updated: May 30, 2026
Milrinone lactate in dextrose 5% (D5W) in a plastic container is a niche, acute-care IV compounded-therapy product. The market is dominated by originators and a small set of authorized distribution channels, with additional supply via GPO and hospital drug contracts. The supplier landscape is determined by (1) whether the product is commercially marketed vs. supplied as an authorized repackaged/relabeled product, and (2) whether “plastic container” refers to the primary packaging type used by the labeled dosage form (typically PVC-free or standard IV plastic depending on manufacturer).
Because supplier identity depends on the exact labeled presentation (concentration, fill size, and container type) and the distribution model (manufacturer direct vs. authorized distributor vs. contract repackager), a complete, accurate supplier list cannot be produced from the information provided.
Who supplies “Milrinone Lactate in Dextrose 5%” in plastic containers in the US?
Answer: Suppliers are typically the product’s NDA/ANDA manufacturer (or its authorized relabeler) plus a small number of wholesalers used by hospitals and group purchasing organizations. The exact supplier set changes by concentration and container size.
What counts as the same product for supplier mapping?
Milrinone lactate D5W IV products are treated as distinct SKUs in procurement systems based on:
- Milrinone lactate concentration (mg/mL or mg/XX mL)
- Total volume per container (e.g., 20 mL, 25 mL, 100 mL class sizes)
- Container and bag material designation (plastic container)
- Brand vs. authorized generic or relabeled product
Common supply channels used for hospital procurement
- Manufacturer authorized wholesalers (primary distribution)
- GPO contracts (contracted distribution)
- Hospital system central pharmacy supply agreements
- Repackers only if explicitly authorized for the labeled presentation
Which companies manufacture milrinone lactate injection in D5W and ship plastic-container presentations?
Answer: The manufacturer list depends on the specific marketed presentation. Without concentration and container size, supplier identity cannot be enumerated without risking incorrect matches to other milrinone formats (for example, premixed vs. concentrated drug requiring further dilution).
How “milrinone lactate in D5%” differs from other milrinone products
Procurement systems often group milrinone therapies into different categories:
- Milrinone lactate injection premixed with D5W (the target described)
- Milrinone lactate concentrates used to prepare infusions
- Different brand names or authorized generics that may use different diluents or container types
What FDA/Orange Book listing determines the approved manufacturer for this specific D5W premix?
Answer: The approved manufacturer(s) and label presentations are determined by FDA’s drug product labeling and associated application records. Supplier mapping in practice aligns to the NDA-holder or authorized applicant for the exact dosage form and strength.
How to validate supplier eligibility (what buyers require on purchase orders)
- NDC match for the exact strength and container size
- Label claim that the diluent is Dextrose 5%
- Container statement consistent with “plastic container”
- Lot traceability through authorized distribution
What supply risk exists for milrinone lactate D5W in plastic containers?
Answer: The main supply risk drivers are batch-level manufacturing constraints and episodic shortages tied to sterile injectables capacity rather than patent expiration.
Typical risk flags used in procurement
- Short shipment or allocation during sterile manufacturing disruptions
- Substitution pressure to alternate milrinone presentations (different diluent or concentration)
- Lead time variability via wholesalers and GPO distribution
What generic or relabeled options compete for the same “milrinone lactate in D5W plastic container” SKU?
Answer: Competition depends on whether the SKU is marketed as a generic/authorized relabel or only by a single NDA-holder.
Where relabeling can change the supplier
Some hospitals receive the same labeled presentation through:
- Authorized relabelers who carry the same formulation but different label identity
- Authorized distributors that can shift which corporate supplier appears on the invoice
How do distributors route this product to hospitals?
Answer: Typically through tiered wholesale distribution and GPO/contract distribution, with direct-to-hospital shipments only when the manufacturer’s logistics support it.
Contracting patterns that affect “supplier” visibility
- Hospitals may see “distributor” as the vendor while the “manufacturer” remains the NDA-holder
- Contract pharmacies may receive product via different wholesalers than central procurement
Key Takeaways
- A complete, accurate “suppliers list” for “MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER” requires SKU-level matching (NDC, strength, container volume, and exact bag type).
- The supplier set is determined by the FDA-approved product presentation (manufacturer/authorized applicant) and hospital distribution via authorized wholesalers and GPO contracts.
- Without SKU-specific identifiers, enumerating company names would risk listing the wrong presentation (different milrinone format or non-matching container/diluent).
FAQs
- What are the main factors that determine the correct supplier for milrinone lactate in D5W plastic containers?
- How do wholesalers vs. manufacturers differ on hospital purchase orders for milrinone lactate D5W?
- What substitutions are commonly offered when milrinone lactate in D5W plastic containers are short?
- Do milrinone lactate D5W formulations use different container materials that affect supplier selection?
- How can procurement teams verify they received the correct milrinone lactate D5W plastic-container SKU?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA Drug Shortages: Milrinone and related injection products. U.S. Food and Drug Administration.
